JP2024516096A5 - - Google Patents

Info

Publication number
JP2024516096A5
JP2024516096A5 JP2023561853A JP2023561853A JP2024516096A5 JP 2024516096 A5 JP2024516096 A5 JP 2024516096A5 JP 2023561853 A JP2023561853 A JP 2023561853A JP 2023561853 A JP2023561853 A JP 2023561853A JP 2024516096 A5 JP2024516096 A5 JP 2024516096A5
Authority
JP
Japan
Prior art keywords
rnai agent
sequence
nucleotide
agent according
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561853A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516096A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/023813 external-priority patent/WO2022216920A1/en
Publication of JP2024516096A publication Critical patent/JP2024516096A/ja
Publication of JP2024516096A5 publication Critical patent/JP2024516096A5/ja
Pending legal-status Critical Current

Links

JP2023561853A 2021-04-08 2022-04-07 終末糖化産物受容体の発現を阻害するためのRNAi剤、その組成物、及び使用方法 Pending JP2024516096A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163172301P 2021-04-08 2021-04-08
US63/172,301 2021-04-08
US202263322603P 2022-03-22 2022-03-22
US63/322,603 2022-03-22
PCT/US2022/023813 WO2022216920A1 (en) 2021-04-08 2022-04-07 Rnai agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use

Publications (2)

Publication Number Publication Date
JP2024516096A JP2024516096A (ja) 2024-04-12
JP2024516096A5 true JP2024516096A5 (enExample) 2025-04-15

Family

ID=83545747

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561853A Pending JP2024516096A (ja) 2021-04-08 2022-04-07 終末糖化産物受容体の発現を阻害するためのRNAi剤、その組成物、及び使用方法

Country Status (15)

Country Link
US (1) US12486502B2 (enExample)
EP (1) EP4319765A4 (enExample)
JP (1) JP2024516096A (enExample)
KR (1) KR20230167082A (enExample)
AU (1) AU2022254705A1 (enExample)
BR (1) BR112023020626A2 (enExample)
CA (1) CA3213968A1 (enExample)
CL (1) CL2023002985A1 (enExample)
CO (1) CO2023013243A2 (enExample)
IL (1) IL307421A (enExample)
MX (1) MX2023011909A (enExample)
PE (1) PE20240766A1 (enExample)
PH (1) PH12023552779A1 (enExample)
TW (1) TW202304474A (enExample)
WO (1) WO2022216920A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024229505A1 (en) * 2023-05-05 2024-11-14 RAGE Biotech Pty Ltd Administration of oligonucleotides
TW202509217A (zh) * 2023-08-24 2025-03-01 大陸商上海拓界生物醫藥科技有限公司 靶向RAGE的RNAi劑及其醫藥用途
CN119709736A (zh) * 2023-09-27 2025-03-28 长春金赛药业有限责任公司 一种新的siRNA、包含其的组合物及用途
TW202516008A (zh) * 2023-09-27 2025-04-16 大陸商上海拓界生物醫藥科技有限公司 含三唑基化合物、製備方法及用途
CN120309684A (zh) * 2024-01-15 2025-07-15 武汉人福创新药物研发中心有限公司 靶向化合物及其用途

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5998203A (en) 1996-04-16 1999-12-07 Ribozyme Pharmaceuticals, Inc. Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
PL350057A1 (en) 1999-02-20 2002-11-04 Merck Patent Gmbh β-ALANINE DERIVATIVES
DE60040274D1 (de) 1999-03-10 2008-10-30 Phogen Ltd Verabreichung von nukleinsäuren und proteinen an zellen
DE19929410A1 (de) 1999-06-26 2000-12-28 Merck Patent Gmbh Inhibitoren des Integrins avß6
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US9994853B2 (en) * 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
EP1575513A4 (en) 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
WO2005051995A2 (en) 2003-11-19 2005-06-09 Curagen Corporation Novel advanced glycosylation end product-specific receptor-like protein and nucleic acids encoding same
EP1791567B1 (en) 2004-08-10 2015-07-29 Alnylam Pharmaceuticals Inc. Chemically modified oligonucleotides
GB0520068D0 (en) 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
US20080213249A1 (en) 2006-07-07 2008-09-04 The Scripps Research Insitute Use of Retro-Aldol Reaction to Generate Reactive Vinyl Ketone for Attachment to Antibody Molecules by Michael Addition Reaction for Use in Immunostaining and Immunotargeting
EP2064244B1 (en) 2006-08-03 2019-06-05 MedImmune Limited ANTIBODIES DIRECTED TO alphaVbeta6 AND USES THEREOF
CN101500548A (zh) 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
WO2009069727A1 (ja) 2007-11-28 2009-06-04 Fujifilm Corporation 生体高分子およびポリペプチドの化学修飾方法
CN102596922A (zh) 2009-10-06 2012-07-18 免疫基因公司 有效的缀合物和亲水性连接体
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
SI2539451T1 (sl) 2010-02-24 2016-04-29 Arrowhead Research Corporation Sestavki za ciljano dostavo sirna
US9920317B2 (en) * 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
WO2013032829A1 (en) 2011-08-26 2013-03-07 Arrowhead Research Corporation Poly(vinyl ester) polymers for in vivo nucleic acid delivery
SG11201404354UA (en) 2012-02-17 2014-10-30 Seattle Genetics Inc ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER
EP2650013A1 (en) 2012-04-10 2013-10-16 Deutsches Krebsforschungszentrum Inhibitors of Receptor for Advanced Glycation-End products (RAGE) for use in treating and/or preventing inflammation- and/or damage-induced cancer
CA2842041A1 (en) 2012-04-18 2013-10-24 Arrowhead Research Corporation Poly(acrylate) polymers for in vivo nucleic acid delivery
JP2014029990A (ja) 2012-06-29 2014-02-13 Sharp Corp 窒化物半導体装置の電極構造およびその製造方法並びに窒化物半導体電界効果トランジスタ
DK2978840T3 (da) 2013-03-26 2020-11-30 Biocant Centro De Inovacao Em Biotecnologia Human blod-hjernebarrieremodel afledt af stamceller
JP2015040181A (ja) 2013-08-20 2015-03-02 学校法人立命館 カロテノイドの新規用途、並びにバリア機能改善薬のスクリーニング方法
CN105980615A (zh) 2013-08-28 2016-09-28 卡里斯生命科学瑞士控股有限公司 寡核苷酸探针及其用途
EP2913064A1 (en) 2014-02-26 2015-09-02 celares GmbH Branched drug-linker conjugates for the coupling to biological targeting molecules
KR101602261B1 (ko) * 2014-04-01 2016-03-10 연세대학교 산학협력단 폴리플렉스 전달 시스템을 포함하는 부정맥 치료 또는 예방용 조성물
CA2945945C (en) 2014-04-15 2023-10-03 The Regents Of The University Of California Bi-terminal pegylated integrin-binding peptides and methods of use thereof
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
EP3270903B1 (en) 2015-03-17 2020-05-06 Arrowhead Pharmaceuticals, Inc. Disulfide-containing alkyne linking agents
AR104754A1 (es) 2015-05-29 2017-08-09 Arrowhead Pharmaceuticals Inc Agentes de unión de tetrapéptido escindibles biológicamente
MX2018015109A (es) 2016-06-06 2019-04-22 Arrowhead Pharmaceuticals Inc Nucleotidos modificados con 5'-ciclo-fosfonato.
JOP20190015A1 (ar) 2016-08-04 2019-02-04 Arrowhead Pharmaceuticals Inc عوامل (ار ان ايه آي) لعدوى فيروس الالتهاب الكبدي الوبائي ب
SI3535397T1 (sl) 2016-11-01 2022-04-29 Arrowhead Pharmaceuticals, Inc. Ligandi alfa-V beta-6 integrina in njihove uporabe
WO2019089765A1 (en) 2017-11-01 2019-05-09 Arrowhead Pharmcaceuticals, Inc. Integrin ligands and uses thereof
JP7420727B2 (ja) 2018-02-17 2024-01-23 アローヘッド ファーマシューティカルズ インコーポレイテッド トリアルキン結合剤及び使用方法
WO2021029896A1 (en) 2019-08-15 2021-02-18 Lifesplice Pharma Llc Splice modulating oligonucleotides targeting receptor for advanced glycation end products and methods of use
EP4496579A2 (en) * 2022-03-22 2025-01-29 Arrowhead Pharmaceuticals, Inc. Subcutaneous delivery of rnai agents for inhibiting expression of receptor for advanced glycation end-products (rage)

Similar Documents

Publication Publication Date Title
JP2024516096A5 (enExample)
JP2025185070A5 (enExample)
JP2020526192A5 (enExample)
JP2024539193A5 (enExample)
JP6899509B2 (ja) 呼吸器疾患関連遺伝子特異的siRNA、そのようなsiRNAを含む二重らせんオリゴRNA構造体およびこれを含む呼吸器疾患予防または治療用組成物
JP2020533334A5 (enExample)
JP2022501040A5 (enExample)
CN102099474B (zh) 用于治疗炎症和赘生性细胞增殖的寡核苷酸
TW201803989A (zh) 拮抗b型肝炎病毒之組成物和藥劑及彼等之用途
JP2008510019A5 (enExample)
JP2023519246A5 (enExample)
CN1247473A (zh) 治疗与呼吸失调和肺部炎症相关的疾病和症状的药剂和方法
TW202221122A (zh) B型肝炎患者之寡核苷酸治療
WO1998023294A9 (en) Agent and method of treatment for diseases and conditions associated with respiratory ailments and lung inflammation
JP2010500291A5 (enExample)
JP4903984B2 (ja) オリゴヌクレオチドのinvivoでの効率を増加するおよび哺乳動物において炎症を阻害するための方法
JP2024520522A5 (enExample)
CN114729360A (zh) 降低病毒分子水平的方法
JP2024544532A (ja) Hbvの処置のための医薬組合せ
JP2008516991A5 (enExample)
JP2015532100A (ja) アンフィレギュリンに特異的な二重鎖オリゴrna、そのような二重鎖オリゴrnaを含む二重鎖オリゴrnaの構造体及びこれを含む呼吸器疾患の予防または治療用の組成物
JP2024023235A5 (enExample)
TWI884297B (zh) mRNA奈米膠囊及其用於製備抗病毒藥物的用途
WO1999045776A1 (en) Treatment of respiratory disease and otitis media
JP2023501352A5 (enExample)